Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IONS
  • CUSIP: 46433010
Key Metrics:
  • Previous Close: $27.22
  • 50 Day Moving Average: $31.89
  • 200 Day Moving Average: $31.21
  • 52-Week Range: $19.59 - $65.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -24.94
  • P/E Growth: -0.60
  • Market Cap: $3.24B
  • Outstanding Shares: 120,919,000
  • Beta: 2.11
  • Net Margins: -128.94%
  • Return on Equity: -126.88%
  • Return on Assets: -25.00%
  • Debt-to-Equity Ratio: 3.63%
  • Current Ratio: 6.28%
  • Quick Ratio: 6.21%
Additional Links:
Companies Related to Ionis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $40.40 (57.26% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateFirmActionRatingPrice TargetDetails
10/17/2016BMO Capital MarketsReiterated RatingOutperform$48.00View Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageBuy$47.00View Rating Details
9/26/2016Piper Jaffray Cos.Reiterated RatingOverweight$46.00View Rating Details
9/11/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
8/13/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
8/11/2016Leerink SwannReiterated RatingHold$36.00View Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00View Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00View Rating Details
8/1/2016Needham & Company LLCBoost Price TargetBuy$55.00 -> $64.00View Rating Details
7/15/2016Jefferies GroupReiterated RatingUnderperform$12.00View Rating Details
5/29/2016JPMorgan Chase & Co.Reiterated RatingHoldView Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$65.00 -> $48.00View Rating Details
6/22/2015Deutsche Bank AGSet Price TargetBuy$78.00View Rating Details
3/2/2015Stifel NicolausDowngradeBuy -> Hold$66.00View Rating Details
3/2/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
12/9/2014LaidlawBoost Price Target$65.00View Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
Current Year EPS Consensus Estimate: $-1.11 EPS
Next Year EPS Consensus Estimate: $-1.03 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.50)($0.45)($0.48)
Q3 20162($0.02)$0.18$0.08
Q4 20162($0.29)($0.08)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 89.65%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
News Icon2 Stocks Attracting Analyst Attention: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Northstar Asset Management Group ... - The Voice Registrar (NASDAQ:IONS) - October 27 at 10:28 AM logoWebcast Alert: Ionis Pharmaceuticals' Third Quarter 2016 Financial Results Conference Call (NASDAQ:IONS) - October 26 at 8:53 AM
News IconNoteworthy Analyst Ratings of Two Stocks: Ionis Pharmaceuticals ... - The Voice Registrar (NASDAQ:IONS) - October 25 at 10:37 AM logoWhy Is the ClearBridge Aggressive Growth Fund Lagging behind Peers? (NASDAQ:IONS) - October 25 at 10:37 AM logoBiogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC (NASDAQ:IONS) - October 24 at 5:28 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Sarepta Therapeutics, Inc ... - The Voice Registrar (NASDAQ:IONS) - October 22 at 5:21 PM
News IconNoteworthy Analyst Ratings of Two Stocks Ionis Pharmaceuticals Inc (NASDAQ:IONS), FedEx Corporation (NYSE:FDX) - The Voice Registrar (NASDAQ:IONS) - October 22 at 5:21 PM
News IconIonis Pharmaceuticals Inc. (IONS) Stock Rating Reaffirmed by BMO Capital Markets - DailyQuint (NASDAQ:IONS) - October 19 at 6:00 PM logoETF’s with exposure to Ionis Pharmaceuticals, Inc. : October 19, 2016 (NASDAQ:IONS) - October 19 at 6:00 PM
News IconUpdate on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) for the day (NASDAQ:IONS) - October 15 at 5:23 PM
News IconWhat are Brokerage Firms Saying About Ionis Pharmaceuticals Inc (NASDAQ:IONS)? - CSZ News (NASDAQ:IONS) - October 14 at 8:48 AM
News IconIs AveXis a Major Threat to Ionis Pharmaceuticals? - (NASDAQ:IONS) - October 14 at 8:48 AM logoIs AveXis a Major Threat to Ionis Pharmaceuticals? (NASDAQ:IONS) - October 14 at 8:48 AM
News IconNoteworthy Analyst Ratings of Two Stocks SFR Group SA (EPA:SFR ... - The Voice Registrar (NASDAQ:IONS) - October 12 at 5:40 PM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : October 12, 2016 (NASDAQ:IONS) - October 12 at 10:48 AM
News IconInsider News of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - FactsReporter (NASDAQ:IONS) - October 11 at 5:51 PM logoNew Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy (NASDAQ:IONS) - October 8 at 10:10 AM
News IconRating Reporting: Does Ionis Pharmace (IONS) Look Good? BMO Capital Upgrades It (NASDAQ:IONS) - October 7 at 5:29 PM
News IconRating Reporting: Does Ionis Pharmace (IONS) Look Good? BMO Capital Upgrades It - Thorold News (NASDAQ:IONS) - October 7 at 10:39 AM
News IconNoteworthy Analyst Ratings of Two Stocks Ionis Pharmaceuticals Inc (NASDAQ:IONS), Northstar Realty Finance Corp ... - The Voice Registrar (NASDAQ:IONS) - October 3 at 5:21 PM logoTrader extends upside position in Ionis (NASDAQ:IONS) - September 30 at 10:48 AM
News IconWhat is the Street Saying About Ionis Pharmaceuticals Inc (NASDAQ:IONS)? - Frisco Fastball (NASDAQ:IONS) - September 29 at 5:36 PM logoIonis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (NASDAQ:IONS) - September 28 at 10:31 AM logoPiper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing - Smarter Analyst (NASDAQ:IONS) - September 27 at 10:17 AM logo3 Stocks That Could Make You Rich (NASDAQ:IONS) - September 27 at 10:17 AM logoBiogen : Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy (NASDAQ:IONS) - September 26 at 5:46 PM logoPiper Jaffray Comments on Ionis Pharmaceuticals Inc (IONS) Following Nusinersen NDA Filing (NASDAQ:IONS) - September 26 at 5:46 PM
News IconHC Trending Hot Stocks! Amphastar Pharmaceuticals Inc (AMPH), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS) - September 26 at 10:16 AM logoIONIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events (NASDAQ:IONS) - September 23 at 5:20 PM
News IconIonis Pharmaceuticals Inc (NASDAQ:IONS) & Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Watch List - Money News (NASDAQ:IONS) - September 23 at 8:36 AM
News IconIonis Pharmaceuticals Inc (NASDAQ:IONS) & Goodyear Tire & Rubber Co (NASDAQ:GT) Watch List - Money News (NASDAQ:IONS) - September 23 at 8:36 AM logoStock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc's Akcea Announces Publication in The Lancet of Clinical ... - Smarter Analyst (NASDAQ:IONS) - September 23 at 8:36 AM logoIonis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data (NASDAQ:IONS) - September 22 at 3:42 PM
News IconAkcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Dise... (NASDAQ:IONS) - September 22 at 3:42 PM logoBiogen Bets on Nusinersen (BIIB, IONS) (NASDAQ:IONS) - September 22 at 3:42 PM
News IconAnalysts Take the Wheel on Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares and Where They Might Be Headed - Frisco Fastball (NASDAQ:IONS) - September 22 at 8:52 AM logoIonis Pharma's (IONS) Akcea Announces Publication of Encouraging Lp(a)-Lowering Drug Data - (NASDAQ:IONS) - September 22 at 8:52 AM logoAkcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease (NASDAQ:IONS) - September 22 at 8:51 AM logoMoves in Cancer Therapeutics among Recent Developments for Ionis (NASDAQ:IONS) - September 22 at 8:51 AM
News IconStock on the Move- Ionis Pharmaceuticals, Inc.'s (IONS) - Hot Stocks Point (NASDAQ:IONS) - September 21 at 3:53 PM
News IconConcerns Diverting Active Stocks Direction: Medtronic (NYSE:MDT), Ionis Pharmaceuticals, Inc. (IONS), AmSurg (AMSG) - Street Wise Report (press release) (blog) (NASDAQ:IONS) - September 16 at 9:35 AM logoIonis Pharmaceuticals' (IONS) Management presents at 2016 Wells Fargo Healthcare Brokers Conference Transcript - Seeking Alpha (NASDAQ:IONS) - September 15 at 6:05 PM logoETF’s with exposure to Ionis Pharmaceuticals, Inc. : September 15, 2016 (NASDAQ:IONS) - September 15 at 6:05 PM
News IconCould Ionis Pharmaceuticals Inc Decline After Today's Huge Increase? - Chester News (NASDAQ:IONS) - September 15 at 8:52 AM logoAkcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome (NASDAQ:IONS) - September 15 at 8:52 AM
News IconHC Stocks Impression= Cytori Therapeutics Inc (CYTX), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) (NASDAQ:IONS) - September 14 at 9:53 AM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 12, 2016 (NASDAQ:IONS) - September 14 at 9:53 AM logoIonis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : September 13, 2016 (NASDAQ:IONS) - September 14 at 9:53 AM
News IconJefferies Group Increases Adeptus Health Inc. (ADPT) Price Target to $100.00 (NASDAQ:IONS) - September 9 at 5:26 PM logoIonis Pharmaceuticals, Inc. (IONS) (NASDAQ:IONS) - September 7 at 9:04 AM


Ionis Pharmaceuticals (NASDAQ:IONS) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff